Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis

Nature Communications

Volumn 7, Issue , 2016, Pages

  Dubin, Krista ^a,b   Callahan, Margaret K ^a,c   Ren, Boyu ^d   Khanin, Raya ^a   Viale, Agnes ^a   Ling, Lilan ^a   No, Daniel ^a   Gobourne, Asia ^a   Littmann, Eric ^a   Huttenhower, Curtis ^d,e   Pamer, Eric G ^a   Wolchok, Jedd D ^a,c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Weill Cornell Graduate School of Biomedical Sciences   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; IPILIMUMAB; POLYAMINE; VEMURAFENIB; VITAMIN B GROUP; MONOCLONAL ANTIBODY; RNA 16S;

ANTIBODY; BIOMARKER; CANCER; CELL ORGANELLE; CELLS AND CELL COMPONENTS; IMMUNE RESPONSE; RISK ASSESSMENT;

ADULT; AGED; ARTICLE; BACTEROIDETES; CLINICAL ARTICLE; COLITIS; FECES ANALYSIS; FECES COMPOSITION; FECES MICROFLORA; HUMAN; INFLAMMATION; INTESTINE FLORA; METASTATIC MELANOMA; MONOTHERAPY; PROSPECTIVE STUDY; PROTEIN SYNTHESIS; PROTEIN TRANSPORT; RISK FACTOR; RISK REDUCTION; BACTEROIDACEAE; CHEMICALLY INDUCED; FEMALE; GENETICS; ISOLATION AND PURIFICATION; MALE; MELANOMA; MICROBIOLOGY; MIDDLE AGED; PATHOLOGY; SECONDARY; SEQUENCE ANALYSIS; SKIN NEOPLASMS; VERY ELDERLY;

BACTEROIDETES PHYLUM;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; BACTEROIDACEAE; BACTEROIDETES; COLITIS; FEMALE; GASTROINTESTINAL MICROBIOME; HUMANS; MALE; MELANOMA; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; RNA, RIBOSOMAL, 16S; SEQUENCE ANALYSIS, RNA; SKIN NEOPLASMS;

EID: 84957565779     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms10391     Document Type: Article

References (38)

1. Caballero, S. & Pamer, E. G. Microbiota-mediated inflammation and antimicrobial defense in the intestine. Annu. Rev. Immunol. 33, 227-256 (2015).
2. Belkaid, Y. & Hand, T. W. Role of the microbiota in immunity and inflammation. Cell 157, 121-141 (2014).
3. Qin, J. et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464, 59-65 (2010).
4. Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature 486, 207-214 (2012).
5. Atarashi, K. et al. Induction of colonic regulatory T cells by indigenous clostridium species. Science 331, 337-341 (2011).
6. Mazmanian, S. K., Liu, C. H., Tzianabos, A. O. & Kasper, D. L. An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell 122, 107-118 (2005).
7. Sokol, H. et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of crohn disease patients. Proc. Natl Acad. Sci. 105, 16731-16736 (2008).
8. Lupp, C. et al. Host-mediated inflammation disrupts the intestinal microbiota and promotes the overgrowth of enterobacteriaceae. Cell Host Microbe 2, 119-129 (2007).
9. Stecher, B. et al. Salmonella enterica serovar typhimurium exploits inflammation to compete with the intestinal microbiota. PLoS Biol. 5, 2177-2189 (2007).
10. Winter, S. E. et al. Host-derived nitrate boosts growth of E. Coli in the inflamed gut. Science 339, 708-711 (2013).
11. Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723 (2010).
12. Berman, D. et al. Blockade of cytotoxic t-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. Cancer Immun. 10, 11-21 (2010).
13. Weber, J. S. et al. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer 119, 1675-1682 (2013).
14. Lord, J. D. et al. Refractory colitis following anti-ctla4 antibody therapy: analysis of mucosal FOXP3 + T cells. Dig. Dis. Sci. 55, 1396-1405 (2010).
15. Gupta, A, De Felice, K.M., Loftus, E.V. & Khanna, S. Systematic review: colitis associated with anti-ctla-4 therapy. Aliment. Pharmacol. Ther. 42, 406-417 (2015).
16. Round, J. L. & Mazmanian, S. K. Inducible Foxp3 + regulatory T-cell development by a commensal bacterium of the intestinal microbiota. Proc. Natl Acad. Sci. USA 107, 12204-12209 (2010).
17. Faith, J. J., Ahern, P. P., Ridaura, V. K., Cheng, J. & Gordon, J. I. Identifying gut microbe-host phenotype relationships using combinatorial communities in gnotobiotic mice. Sci. Transl. Med. 6, 220ra11 (2014).
18. Hill, M. J. Intestinal flora and endogenous vitamin synthesis. Eur. J. Cancer Prev. 6, S43-S45 (1997).
19. Gill, S. R. et al. Metagenomic analysis of the human distal gut microbiome. Science 312, 1355-1359 (2006).
20. Coates, M. E., Ford, J. E. & Harrison, G. F. Intestinal synthesis of vitamins of the B complex in chicks. Br. J. Nutr. 22, 493-500 (1968).
21. Kuroki, F. et al. Multiple vitamin status in crohn's disease. Dig. Dis. Sci. 38, 1614-1618 (1993).
22. Ellestad-Sayed, J. J., Nelson, R. A., Adson, M. A., Palmer, W. M. & Soule, E. H. Pantothenic acid, coenzyme A, and human chronic ulcerative and granulomatous colitis. Am. J. Clin. Nutr. 29, 1333-1338 (1976).
23. Kjer-Nielsen, L. et al. (2012MR1 presents microbial vitamin B metabolites to MAIT cells. Nature 491, 717-723.
24. Serriari, N. E. et al. Innate mucosal-associated invariant T (MAIT) cells are activated in inflammatory bowel diseases. Clin. Exp. Immunol. 176, 266-274 (2014).
25. Furuchi, T., Kashiwagi, K., Kobayashi, H. & Igarashi, K. Characteristics of the gene for a spermidine and putrescine transport system that maps at 15 min on the escherichia coli chromosome. J. Biol. Chem. 266, 20928-20933 (1991).
26. Ricci, G. et al. Ornithine decarboxylase in colonic mucosa from patients with moderate or severe Crohn's disease and ulcerative colitis. Eur. J. Gastroenterol. Hepatol. 11, 903-904 (1999).
27. Weiss, T. S. et al. Intracellular polyamine levels of intestinal epithelial cells in inflammatory bowel disease. Inflamm. Bowel Dis. 10, 529-535 (2004).
28. Topalian, S. L. et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J. Clin. Oncol. 32, 1020-1030 (2014).
29. Sivan, A. et al. Commensal bifidobacterium promotes antitumor immunity and facilitates anti-pd-l1 efficacy. Science 350, 1084-1089 (2015).
30. Vétizou, M. et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 350, 1079-1084 (2015).
31. Iida, N. et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 342, 967-970 (2013).
32. Viaud, S. et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 342, 971-976 (2013).
33. Schloss, P. D. et al. Introducing mothur: Open-source, platform-independent, community-supported software for describing and comparing microbial communities. Appl. Environ. Microbiol. 75, 7537-7541 (2009).
34. Edgar, R. C., Haas, B. J., Clemente, J. C., Quince, C & Knight, R. UCHIME improves sensitivity and speed of chimera detection. Bioinformatics 27, 2194-2200 (2011).
35. Abubucker, S. et al. Metabolic reconstruction for metagenomic data and its application to the human microbiome. PLoS Comput. Biol. 8, e1002358 (2012).
36. Kanehisa, M., Goto, S., Furumichi, M., Tanabe, M. & Hirakawa, M. KEGG for representation and analysis of molecular networks involving diseases and drugs. Nucleic Acids Res. 38, D355-D360 (2010).
37. Segata, N. et al. Metagenomic microbial community profiling using unique clade-specific marker genes. Nat. Methods 9, 811-814 (2012).
38. Segata, N. et al. Metagenomic biomarker discovery and explanation. Genome Biol. 12, R60 (2011).